Boothwyn Pharmacy
Pennsylvania 503A compounder (221 Gale Lane) listed in Shed's terms. FDA's January 2026 warning letter cites subpotent semaglutide and failed tirzepatide lots, and the pharmacy stopped making sterile GLP-1 products.
Legal name: Boothwyn Pharmacy LLC
Makes or dispenses: semaglutide, tirzepatide
Telehealth brands that use Boothwyn Pharmacy
FDA and regulatory record
Warning letters and Form 483s record problems FDA found during an inspection at the time. They don't by themselves mean the medication you receive today is unsafe, and pharmacies often fix the issues. Check the dates, and read the source documents.
- Jan 16, 2026 · FDA warning letter
Insanitary conditions. Semaglutide 2.5 mg/mL tested subpotent (about 79.9%), and tirzepatide lots failed potency and sterility tests.
Source → - Jul 9, 2025 · Recall
Voluntary recall of all drug products with out-of-specification results (per the FDA warning letter).
Source → - Jun 9, 2025 · Form 483
Inspection from May 12 to June 9, 2025 found insanitary conditions and out-of-spec GLP-1 lots.
Source →
Questions about Boothwyn Pharmacy
Which telehealth companies use Boothwyn Pharmacy?
▾
Among the brands we track: Shed. Each of these brands names the pharmacy in its own materials.
What kind of pharmacy is Boothwyn Pharmacy?
▾
Boothwyn Pharmacy is listed as: 503a compounding pharmacy, based in Kennett Square, PA. 503A pharmacies compound medication for individual patient prescriptions under state board oversight; 503B outsourcing facilities register with the FDA and follow federal manufacturing standards (CGMP).
Has Boothwyn Pharmacy received FDA warning letters?
▾
We found 3 regulatory records, the most recent dated Jan 16, 2026. Each is listed on this page with a link to the source document.
Sources
- https://www.tryshed.com/terms
- https://www.einpresswire.com/article/891062014/boothwyn-pharmacy-llc-717525-01-16-2026
Researched 2026-09-26.